Logo image of ZEG.DE

ASTRAZENECA PLC (ZEG.DE) Stock Overview

Europe - FRA:ZEG - GB0009895292 - Common Stock

143.85 EUR
+0.45 (+0.31%)
Last: 10/27/2025, 7:00:00 PM

ZEG.DE Key Statistics, Chart & Performance

Key Statistics
Market Cap446.01B
Revenue(TTM)56.50B
Net Income(TTM)8.29B
Shares3.10B
Float2.99B
52 Week High149.5
52 Week Low111
Yearly Dividend2.57
Dividend Yield1.96%
EPS(TTM)7.6
PE18.93
Fwd PE15.76
Earnings (Next)11-06 2025-11-06/bmo
IPO2007-09-21
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals


ZEG.DE short term performance overview.The bars show the price performance of ZEG.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 10

ZEG.DE long term performance overview.The bars show the price performance of ZEG.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years 5 10 15 20

The current stock price of ZEG.DE is 143.85 EUR. In the past month the price increased by 13.31%. In the past year, price increased by 9.27%.

ASTRAZENECA PLC / ZEG Daily stock chart

ZEG.DE Competitors/Peers

The largest stocks on the EU markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
1LLY.MI ELI LILLY & CO 50.7 667.44B
LLY.DE ELI LILLY & CO 50.72 667.73B
1JNJ.MI JOHNSON & JOHNSON 18.29 393.86B
JNJ.DE JOHNSON & JOHNSON 18.26 393.23B
RHO.DE ROCHE HOLDING AG-BR 14.13 243.26B
1ROG.MI ROCHE HOLDING AG-GENUSSCHEIN 13.92 239.54B
1NOVN.MI NOVARTIS AG-REG 14.74 214.88B
NOT.DE NOVARTIS AG-REG 14.8 215.73B
1SAN.MI SANOFI 14.36 215.27B
SNW.DE SANOFI 14.36 215.27B
SAN.PA SANOFI 14.33 214.78B
NOV.DE NOVO NORDISK A/S-B 13.64 202.44B

About ZEG.DE

Company Profile

ZEG logo image AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.

Company Info

ASTRAZENECA PLC

1 Francis Crick Avenue, Cambridge Biomedical Campus

CAMBRIDGE CAMBRIDGESHIRE GB

Employees: 94300

ZEG Company Website

ZEG Investor Relations

Phone: 442073045000

ASTRAZENECA PLC / ZEG.DE FAQ

What does ZEG do?

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.


What is the current price of ZEG stock?

The current stock price of ZEG.DE is 143.85 EUR. The price increased by 0.31% in the last trading session.


Does ZEG stock pay dividends?

ASTRAZENECA PLC (ZEG.DE) has a dividend yield of 1.96%. The yearly dividend amount is currently 2.57.


What is the ChartMill rating of ASTRAZENECA PLC stock?

ZEG.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


What is the expected growth for ZEG stock?

The Revenue of ASTRAZENECA PLC (ZEG.DE) is expected to grow by 9.63% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


What is the employee count for ZEG stock?

ASTRAZENECA PLC (ZEG.DE) currently has 94300 employees.


ZEG.DE Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to ZEG.DE. When comparing the yearly performance of all stocks, ZEG.DE turns out to be only a medium performer in the overall market: it outperformed 61.75% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ZEG.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to ZEG.DE. ZEG.DE scores excellent on profitability, but there are concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZEG.DE Financial Highlights

Over the last trailing twelve months ZEG.DE reported a non-GAAP Earnings per Share(EPS) of 7.6. The EPS increased by 22.3% compared to the year before.


Industry RankSector Rank
PM (TTM) 14.68%
ROA 7.38%
ROE 18.55%
Debt/Equity 0.63
Chartmill High Growth Momentum
EPS Q2Q%9.6%
Sales Q2Q%11.74%
EPS 1Y (TTM)22.3%
Revenue 1Y (TTM)15%

ZEG.DE Forecast & Estimates

33 analysts have analysed ZEG.DE and the average price target is 154.88 EUR. This implies a price increase of 7.67% is expected in the next year compared to the current price of 143.85.

For the next year, analysts expect an EPS growth of 13.74% and a revenue growth 9.63% for ZEG.DE


Analysts
Analysts81.82
Price Target154.88 (7.67%)
EPS Next Y13.74%
Revenue Next Year9.63%

ZEG.DE Ownership

Ownership
Inst Owners48.98%
Ins Owners0.04%
Short Float %N/A
Short RatioN/A